Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 4/2020

01-10-2020 | COVID-19 | Review Article

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

Authors: Arihant Jain, Charanpreet Singh, Rishi Dhawan, Nishant Jindal, Ritin Mohindra, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Vikas Suri, Ashish Bhalla, Savita Kumari, Neelam Varma, M Joseph John, Manoranjan Mahapatra, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2020

Login to get access

Abstract

The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.
Literature
1.
Wang H, Zhang L (2020) Risk of COVID-19 for patients with cancer. Lancet Oncol 21(4):e181CrossRef
2.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062CrossRef
3.
Desai A, Sachdeva S, Parekh T, Desai R (2020) Covid-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 6:557–559CrossRef
4.
5.
Minnema BJ, Husain S, Mazzulli T, Hosseini-Mogaddam SM, Patel M, Brandwein J et al (2013) Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study. Leuk Lymphoma 54(6):1250–1255CrossRef
6.
Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Campuzano JBN, Cannata-Ortiz MJ et al (2011) Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 96(8):1231–1235CrossRef
7.
Dignani MC, Costantini P, Salgueira C, Jordán R, Guerrini G, Valledor A et al (2015) Pandemic 2009 influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000 Res 3:221CrossRef
8.
9.
10.
Ambroise MM, Ravichandran K, Ramdas A, Sekhar G (2015) A study of blood utilization in a tertiary care hospital in South India. J Nat Sci Biol Med 6(1):106–110CrossRef
11.
Kamel Boulos MN, Geraghty EM (2020) Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbr. Int J Health Geogr 19(1):8CrossRef
12.
13.
14.
Willan J, King AJ, Hayes S, Collins GP, Peniket A (2020) Care of haematology patients in a COVID-19 epidemic. Br J Haematol 189(2):241–243CrossRef
15.
Board of Governors (2020) In supersession of the Medical Council of India telemedicine practice guidelines enabling registered medical practitioners to provide healthcare using telemedicine. www.​mohfw.​gov.​in. Accessed on 14 Apr 2020
16.
17.
18.
19.
20.
Banavali SD (2015) Delivery of cancer care in rural India: experiences of establishing a rural comprehensive cancer care facility. Indian J Med Paediatr Oncol 36(2):128CrossRef
21.
Ministry of Health and Family Welfare Directorate General of Health Services [emergency medical relief] novel corornavirus disease (COVID-19) guidelines on use of masks by public. www.​moohfw.​gov.​in. Accessed on 14 Apr 2020
22.
23.
24.
Ben-Bassat I, Douer D, Ramot B (2009) Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. Eur J Haematol 45(2):86–89CrossRef
25.
26.
Lancet T (2020) Palliative care and the COVID-19 pandemic. The Lancet 395(10231):1168
27.
Favre G, Fopp M, Gmür J, Tichelli A, Fey MF, Tobler A et al (1993) Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol 67(4):153–160CrossRef
28.
Lopez-Plaza I, Weissfeld J, Triulzi DJ (1999) The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 39(9):925–932CrossRef
29.
30.
Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F et al (2015) Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 125(24):3711–3719CrossRef
31.
McNeer JL, Nachman JB (2010) The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 149(5):638–652CrossRef
32.
Grunwald MR, Boselli D, Bohannon LM, Zimmerman MKA, Ai J, Knight TG et al (2018) Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML). J Clin Oncol 36(15 suppl):7033–7033CrossRef
33.
Kim Y, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ et al (2014) Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. Int J Hematol 99(5):635–643CrossRef
34.
Wu D, Duan C, Chen L, Chen S (2017) Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep 7(1):9509CrossRef
35.
36.
Varma S, Yanamandra U, Khadwal A, Prakash G, Suri V, Kumari S et al (2015) High risk apml treated successfully with four cycles of ATO and ATRA combination in resource constrained settings. Blood 126(23):3322–3322CrossRef
37.
Jastaniah W, Elimam N, Abdalla K, AlAzmi AA, Aseeri M, Felimban S (2018) High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia. Leuk Res Rep 10:44–51PubMedPubMedCentral
38.
Dunleavy K (2018) Approach to the diagnosis and treatment of adult burkitt’s lymphoma. J Oncol Pract 14(11):665–671CrossRef
39.
40.
Coiffier B, Sarkozy C (2016) Diffuse large B-cell lymphoma: R-CHOP failure–What to do? Hematology 2016(1):366–378CrossRef
41.
Avilés A, Jesús Nambo M, Neri N (2013) Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3258 patients in a single center. Med Oncol 30(2):520CrossRef
42.
43.
44.
45.
46.
Deng S, Lin S, Shen J, Zeng Y (2019) Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. Onco Targets Ther 12:2335–2342CrossRef
47.
48.
49.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059–3068CrossRef
50.
51.
Gration B, Duran A, Mir N, Yuen L, Warner M, Stanley K et al (2017) R-GCVP as second line treatment in elderly patients with DLBCL who fail R-CHOP and are not candidates for intensive therapy. Blood 130(Supplement 1):4133–4133
52.
53.
Ganesan P, Kumar L (2017) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64–71CrossRef
54.
Copeland A, Wehbie R, Clayton M, Black A, Rapchak B, Foster MC (2015) The feasibility of a telemedicine platform to monitor adherence and adverse effects of ABL kinase inhibitors. Blood 126(23):3308–3308CrossRef
55.
56.
57.
58.
Little P (2020) Non-steroidal anti-inflammatory drugs and covid-19. BMJ 368:m1185CrossRef
59.
Russell B, Moss C, Rigg A, Van Hemelrijck M (2020) COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience 14:1023PubMedPubMedCentral
60.
Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM (2018) Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera. Blood Cancer J 8(12):124CrossRef
61.
62.
Hö Chsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H (2013) Supportive care in severe and very severe aplastic anemia. Bone Marrow Transpl 48:168–173CrossRef
63.
64.
ten Cate H (2020) Thrombosis management in times of COVID-19 epidemy; a dutch perspective. Thromb J 18(1):7CrossRef
65.
66.
67.
Metadata
Title
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
Authors
Arihant Jain
Charanpreet Singh
Rishi Dhawan
Nishant Jindal
Ritin Mohindra
Deepesh Lad
Gaurav Prakash
Alka Khadwal
Vikas Suri
Ashish Bhalla
Savita Kumari
Neelam Varma
M Joseph John
Manoranjan Mahapatra
Pankaj Malhotra
Publication date
01-10-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01300-0

Other articles of this Issue 4/2020

Indian Journal of Hematology and Blood Transfusion 4/2020 Go to the issue

Original Article

Quantification of Liver Iron Overload: Correlation of MRI and Liver Tissue Biopsy in Pediatric Thalassemia Major Patients Undergoing Bone Marrow Transplant

Correspondence

A Rare Case of Spontaneous Splenic Rupture in Refractory Mantle Cell Lymphoma

Original Article

Distribution of BCR–ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia

Original Article

Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival

Short Communication

A Pilot Study to Assess Transfusion Transmission of Hepatitis C Virus

Original Article

Role of Hematological Indices as a Screening Tool of Beta Thalassemia Trait in Eastern Uttar Pradesh: An Institutional Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits